Iovance Biotherapeutics Inc (IOVA) Stock Price, Quote & News

Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanom...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 260 7120

Website: www.iovance.com

Address:

825 Industrial Road, Suite 100, San Carlos, United States

saitek88 Aug. 27 at 3:35 AM

$IOVA $NVDA is the last chance for us to get out from this market alive. I heard the reason we did not see collapse yet is because they believe $NVDA ER will be good. But after that..... this market will have mini correction folks. Sadly....

1 · Reply

Princess88 Aug. 27 at 3:12 AM

$IOVA Dear everyone… We really need good news to overcome the ATM news. Dilution news is never good for any stock, especially biotech. Tech stocks like $INTC $NVDA they do dilute too but shares even up after the news, for example, $INTC and SoftBank $2B equity investment. We are still in the accumulation channel, between $1.80 to $2.50 range. When market deteriorates people will sell risky assets like biotech first. Good stocks will be the last to fall. If you want to buy more $IOVA shares, buy at lower end of the accumulation channels, lower end = near $1.80, higher end = near $2.50.

1 · Reply

TumorInfiltratingLegend Aug. 27 at 3:06 AM

$IOVA get ready to be dissapointed on nsclc data. From "registrational data completed this year" to "updated interim data from registrational this year". What an absolute shitshow this management team is. Scumbags

1 · Reply

saitek88 Aug. 27 at 2:35 AM

$IOVA Hilarious....talking to my friend who is professional trader, he's already 80% in cash. Lol. Hope $NVDA ER will save the market for a few days so I can do the same. I don't like how the market acting whatsoever....

1 · Reply

Bullishtechie Aug. 27 at 2:31 AM

$IOVA Round the clock shorted by management criminals

0 · Reply

FoundMuhMoney Aug. 27 at 2:15 AM

$IOVA Replimune a “competitor” with a CRL up 3.4% today. Us with an approved therapy working out kinks down 3%. Totally makes sense. Hold those shares.

1 · Reply

saitek88 Aug. 27 at 12:54 AM

$IOVA September will be a very bearish month for the stock market in general. Have you noticed something? Stocks are being sold off heavily... Fake head up in the morning so they can dump shares to investors. It already happening, including technology stocks. Fade everywhere.... Becareful in the market from now until the end of September folks. It's not going to be pretty.

2 · Reply

KeyImpatience Aug. 26 at 11:29 PM

$IOVA I’d imagine money will move in throughout the month of September in anticipation of data readouts Mid-Oct. slow grind up to $4 maybe?

2 · Reply

Mango_Paris Aug. 26 at 11:26 PM

$IOVA Looking back from 2023: dilution n draws of the company. Just figured out with simple Regression techniques that this year the company will dilute about 9-12 million shares (23-30 million) by end of Dec 2025 and (78 - 103) million by the end of 2026. So, if the catalyst is positive: play with the volatility and take profits and be out. Please don’t hold too long. It will be painful if you see the price at 1.40 where most of the options are priced in long run (GBM n stochastic)

1 · Reply

FE123 Aug. 26 at 11:22 PM

$IOVA $TGTX $ALTS Go!!

0 · Reply

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Aug 21, 2025, 4:56 PM EDT - 5 days ago

Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25

Aug 18, 2025, 4:15 PM EDT - 8 days ago

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Aug 8, 2025, 3:15 AM EDT - 18 days ago

Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 19 days ago

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

Jul 23, 2025, 12:08 PM EDT - 4 weeks ago

Here's why Iova stock surged 32% today and why the rally might not be over

Jul 18, 2025, 12:02 PM EDT - 5 weeks ago

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug

Jul 15, 2025, 7:30 AM EDT - 6 weeks ago

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

Jul 14, 2025, 9:04 AM EDT - 6 weeks ago

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Jul 14, 2025, 7:30 AM EDT - 6 weeks ago

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

Jul 11, 2025, 10:32 AM EDT - 6 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jul 10, 2025, 4:01 PM EDT - 6 weeks ago

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

Jul 10, 2025, 8:18 AM EDT - 6 weeks ago

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

Jul 3, 2025, 7:35 AM EDT - 7 weeks ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jul 2, 2025, 5:46 PM EDT - 7 weeks ago

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure– Hagens Berman

Jun 28, 2025, 7:46 AM EDT - 2 months ago

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 26, 2025, 4:45 PM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA

Jun 26, 2025, 9:00 AM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA

Jun 24, 2025, 12:03 PM EDT - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics

Jun 20, 2025, 9:07 AM EDT - 2 months ago

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 18, 2025, 2:34 PM EDT - 2 months ago

Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure – Hagens Berman

Jun 18, 2025, 8:38 AM EDT - 2 months ago

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

Jun 16, 2025, 8:17 AM EDT - 2 months ago

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 10, 2025, 8:47 AM EDT - 2 months ago

IOVA LEGAL NOTICE: Lose Money when Iovance Biotherapeutics, Inc. Stock Plummeted 44%? Contact BFA Law by the July 14 Court Deadline (NASDAQ:IOVA)

Jun 10, 2025, 8:45 AM EDT - 2 months ago

Iovance Biotherapeutics to Present at Upcoming Conference

Jun 8, 2025, 8:18 AM EDT - 2 months ago

IOVA INVESTOR NEWS: Iovance Biotherapeutics, Inc. has been Sued for Securities Fraud – Contact BFA Law before July 14 Deadline (NASDAQ:IOVA)

saitek88 Aug. 27 at 3:35 AM

1 · Reply

Princess88 Aug. 27 at 3:12 AM

1 · Reply

TumorInfiltratingLegend Aug. 27 at 3:06 AM

1 · Reply

saitek88 Aug. 27 at 2:35 AM

1 · Reply

Bullishtechie Aug. 27 at 2:31 AM

$IOVA Round the clock shorted by management criminals

0 · Reply

FoundMuhMoney Aug. 27 at 2:15 AM

$IOVA Replimune a “competitor” with a CRL up 3.4% today. Us with an approved therapy working out kinks down 3%. Totally makes sense. Hold those shares.

1 · Reply

saitek88 Aug. 27 at 12:54 AM

2 · Reply

KeyImpatience Aug. 26 at 11:29 PM

$IOVA I’d imagine money will move in throughout the month of September in anticipation of data readouts Mid-Oct. slow grind up to $4 maybe?

2 · Reply

Mango_Paris Aug. 26 at 11:26 PM

1 · Reply

FE123 Aug. 26 at 11:22 PM

$IOVA $TGTX $ALTS Go!!

0 · Reply

RumRunna Aug. 26 at 11:12 PM

$IOVA a time was had 🍹🍹

1 · Reply

Always_neutral Aug. 26 at 11:03 PM

$IOVA Just back from two weeks vacation. I see a number of new faces but only few from my time. Let's make a shout 😁! I believe things will change for good and soon even with this inept management. Waiting for few days to load more. GLTA

1 · Reply

ztocklydotcom Aug. 26 at 10:39 PM

$IOVA this is why we drew that chart

6 · Reply

fedupfeds Aug. 26 at 10:10 PM

$IOVA If one of trial readouts comes out positive while shorts are heavy, the upside move will be violent.

1 · Reply

JoeBio Aug. 26 at 10:01 PM

$IOVA not one bit. You think his shares are just sitting there or being loaned out on a daily basis? Probably made back enough cake to cover majority of his position cost

1 · Reply

dogbone98 Aug. 26 at 9:51 PM

$IOVA Will be interesting to see if any shorts closed out on that 34M day Aug 19 (CA approval). Will have to wait another couple weeks to see. Meanwhile, just waiting for that mythological creature called the "catalyst" to show up.

0 · Reply

FE123 Aug. 26 at 9:44 PM

$IOVA Shorts at it again!

0 · Reply

ianleung Aug. 26 at 9:42 PM

$IOVA SI rises but short position percentage drops from 20.27% to 19.72%🤔

2 · Reply

beachsidefreddy Aug. 26 at 9:39 PM

$IOVA SI UP A LITTLE GOOD MORE BEATINGS: 08/15/2025 71,364,792 5.40 16,989,216(average volume) 4.20 DTC

0 · Reply

ajtrades02 Aug. 26 at 9:31 PM

$IOVA when a company shows you that they are growing and making revenue with a plan raising cash shouldn’t worry you… let’s work 🧬

1 · Reply

TumorInfiltratingLegend Aug. 26 at 9:16 PM

$IOVA trades like a pre-clinical bio because gross margins are near 0

2 · Reply

Lolichocho Aug. 26 at 8:52 PM

$PHAT $IOVA this is how you do biotech. Watch and learn.

2 · Reply

Market Cap	973.39M
Revenue (ttm)	164.07M
Net Income (ttm)	-372.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-226.84%
Debt to Equity Ratio	0.00

Volume	8,260,000
Avg Vol	18,353,770
Day's Range	N/A - N/A
Shares Out	361.85M
Stochastic %K	20%
Beta	0.88
Analysts	Sell
Price Target	$9.10